Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)

被引：25

作者：

Cornelissen, Robin ^{[1
]}

Prelaj, Arsela ^{[2
,3
]}

Sun, Sophie ^{[4
]}

Baik, Christina ^{[5
]}

Wollner, Mirjana ^{[6
]}

Haura, Eric B. ^{[7
]}

Mamdani, Hirva ^{[8
,9
]}

Riess, Jonathan W. ^{[10
,11
]}

Cappuzzo, Federico ^{[12
]}

Garassino, Marina C. ^{[13
]}

Heymach, John V. ^{[14
]}

Socinski, Mark A. ^{[15
]}

Leu, Szu-Yun ^{[16
]}

Bhat, Gajanan ^{[16
]}

Lebel, Francois ^{[16
]}

Le, Xiuning ^{[14
]}

机构：

[1] Erasmus MC Canc Inst, Pulm Med, Rotterdam, Netherlands

[2] Fdn Ist Ricovero & Cura Carattere Sci IRCCS, Ist Nazl Tumori Milano, Med Oncol, Milan, Italy

[3] Politecn Milan, Dept Elect Informat & Bioengn, Milan, Italy

[4] British Columbia Canc Ctr, Med Oncol, Vancouver, BC, Canada

[5] Seattle Canc Ctr Alliance, Seattle, WA USA

[6] Rambam Hlth Care Campus, Med Oncol, Haifa, Israel

[7] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL USA

[8] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI USA

[9] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[10] Univ Calif Davis, Sch Med, Div Hematol & Oncol, Dept Internal Med, Sacramento, CA USA

[11] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA

[12] Natl Canc Inst IRCCS Regina Elena, Dept Oncol, Rome, Italy

[13] Univ Chicago, Hematol Oncol Sect, Dept Med, Knapp Ctr Biomed Discovery, Chicago, IL USA

[14] Univ Texas MD Anderson Canc Ctr Houston, Dept Thorac Head & Neck Med Oncol, Houston, TX USA

[15] AdventHlth Canc Inst, Thorac Oncol Program, Orlando, FL USA

[16] Spectrum Pharmaceut, Res Dev, Irvine, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 08期

关键词：

KINASE DOMAIN; ANTITUMOR-ACTIVITY; SOMATIC MUTATIONS; CANCER; EGFR; HM781-36B; INHIBITOR;

D O I：

10.1016/j.jtho.2023.03.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1031 / 1041

页数：11

共 50 条

[31] Brightline-4: A phase 3 open-label, single-arm, multicenter study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naive or pretreated advanced dedifferentiated liposarcoma
Schuetze, Scott
Jayadeva, Girish
Santoro, Michael
CANCER RESEARCH, 2024, 84 (07)
[32] Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088
Loong, H. H. F.
Daniele, G.
Yang, T-Y.
Leal, T. A.
Goto, K.
Shinno, Y.
Nishino, K.
Sakamoto, T.
Felip, E.
Ruffinelli, J. C.
Gallot, N.
Wang, Z.
Chen, C.
Brennan, B.
Pu, S-F.
Kornacker, M.
Grassi, P.
Le, X.
Tan, D. S. W.
Goh, B-C.
ANNALS OF ONCOLOGY, 2023, 34
[33] Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial
Hyman, D. M.
Piha-Paul, S. A.
Rodon, J.
Saura, C.
Puzanov, I.
Shapiro, G. I.
Loi, S.
Joensuu, H.
Hanrahan, A. J.
Modi, S.
Lalani, A. S.
Xu, F.
Garza, S. J.
Cutler, R. E.
Bryce, R.
Meric-Bernstam, F.
Baselga, J.
Solit, D. B.
CANCER RESEARCH, 2016, 76
[34] Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial
Kaufman, P. A.
Pernas, S.
Martin, M.
Gil-Martin, M.
Gomez Pardo, P.
Sara, L. T.
Manso, L.
Ciruelos, E.
Perez-Fidalgo, J. A.
Hernando, C.
Ademuyiwa, F. O.
Weilbaecher, K.
Mayer, I.
Pluard, T. J.
Martinez Garcia, M.
Vahdat, L.
Wach, A.
Barker, D.
Romagnoli, B.
Cortes, J.
EUROPEAN JOURNAL OF CANCER, 2018, 92 : S117 - S118
[35] Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial
Eholie, Serge P.
Ekouevi, Didier K.
Chazallon, Corine
Charpentier, Charlotte
Messou, Eugene
Diallo, Zelica
Zoungrana, Jacques
Minga, Albert
Gueye, Ndeye Fatou Ngom
Hawerlander, Denise
Dembele, Fassery
Colin, Geraldine
Tchounga, Boris
Karcher, Sophie
Le Carrou, Jerome
Tchabert-Guie, Annick
Toni, Thomas-d'Aquin
Ouedraogo, Abdoul-Salam
Bado, Guillaume
Kane, Coumba Toure
Seydi, Moussa
Poda, Armel
Mensah, Ephrem
Diallo, Illah
Drabo, Youssouf Joseph
Anglaret, Xavier
Brun-Vezinet, Francoise
LANCET HIV, 2024, 11 (06): : e380 - e388
[36] Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
Yu, Yongfeng
Guo, Qisen
Zhang, Yongchang
Fang, Jian
Zhong, Diansheng
Liu, Baogang
Pan, Pinhua
Lv, Dongqing
Wu, Lin
Zhao, Yanqiu
Li, Juan
Liu, Zhihua
Liu, Chunling
Su, Haichuan
Fan, Yun
Zhang, Tongmei
Liu, Anwen
Jin, Bo
Wang, Ye
Zhou, Jianying
Zhang, Zhihong
Ran, Fengming
Song, Xia
Shi, Michael
Su, Weiguo
Lu, Shun
LANCET RESPIRATORY MEDICINE, 2024, 12 (12): : 958 - 966
[37] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02)
Meric-Bernstam, Funda
Anoka, Chiedozie
Dobrowolska, Anna
Chaudhry, Anubhavini
Rowbottom, Jacqui
Gustavson, Mark
Puvvada, Soham D.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[38] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02)
Meric-Bernstam, Funda
Anoka, Chiedozie
Dobrowolska, Anna
Chaudhry, Anubhavini
Rowbottom, Jacqui
Gustavson, Mark
Puvvada, Soham
GYNECOLOGIC ONCOLOGY, 2022, 166 : S156 - S156
[39] PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.
Llombart-Cussac, Antonio
Perez-Garcia, Jose Manuel
Bellet, Meritxell
Dalenc, Florence
Gil, Miguel J. Gil
Borrego, Manuel Ruiz
Gavila, Joaquin
Sampayo-Cordero, Miguel
Aguirre, Elena
Schmid, Peter
Marme, Frederik
Di Cosimo, Serena
Gligorov, Joseph
Schneeweiss, Andreas
Albanell, Joan
Zamora, Pilar
Wheatley, Duncan
Martinez-De Duenas, Eduardo
Amillano, Kepa
Cortes, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[40] Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL/SLL (RESONATE-2, PCYC-1115-CA).
Burger, Jan Andreas
Ghia, Paolo
Polliack, Aaron
Tam, Constantine
Suri, Deepali
Clow, Fong
Kraljevic, Silvija
James, Candle Frances
Kipps, Thomas J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →